223 related articles for article (PubMed ID: 18556201)
1. N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard.
Jiang Y; Hu L
Bioorg Med Chem Lett; 2008 Jul; 18(14):4059-63. PubMed ID: 18556201
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA).
Jiang Y; Dipaola RS; Hu L
Bioorg Med Chem Lett; 2009 May; 19(9):2587-90. PubMed ID: 19345094
[TBL] [Abstract][Full Text] [Related]
3. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
4. Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA).
Jiang Y; Hu L
Bioorg Med Chem; 2013 Dec; 21(23):7507-14. PubMed ID: 24139844
[TBL] [Abstract][Full Text] [Related]
5. An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation.
Adidala R; Devalapally H; Srivari C; Devarakonda R K; Akkinepally RR
Drug Dev Ind Pharm; 2012 Sep; 38(9):1047-53. PubMed ID: 22185667
[TBL] [Abstract][Full Text] [Related]
6. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
7. Thermodynamic analysis of the reaction of phosphoramide mustard with protector thiols.
Seitz DE; Katterjohn CJ; Rinzel SM; Pearce HL
Cancer Res; 1989 Jul; 49(13):3525-8. PubMed ID: 2499418
[TBL] [Abstract][Full Text] [Related]
8. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
10. Investigation on cyclophosphamide treatment during the preimplantation period. II. In vitro studies on the effects of cyclophosphamide and its metabolites 4-OH-cyclophosphamide, phosphoramide mustard, and acrolein on blastulation of four-cell and eight-cell mouse embryos and on their subsequent development during implantation.
Spielmann H; Jacob-Müller U
Teratology; 1981 Feb; 23(1):7-13. PubMed ID: 7245091
[TBL] [Abstract][Full Text] [Related]
11. DNA cross-linking and single-strand breaks induced by teratogenic concentrations of 4-hydroperoxycyclophosphamide and phosphoramide mustard in postimplantation rat embryos.
Little SA; Mirkes PE
Cancer Res; 1987 Oct; 47(20):5421-6. PubMed ID: 3477317
[TBL] [Abstract][Full Text] [Related]
12. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry.
Yuan ZM; Smith PB; Brundrett RB; Colvin M; Fenselau C
Drug Metab Dispos; 1991; 19(3):625-9. PubMed ID: 1680629
[TBL] [Abstract][Full Text] [Related]
13. Alkylating properties of phosphoramide mustard.
Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C
Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
[TBL] [Abstract][Full Text] [Related]
14. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
15. Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: synthesis, stability, and stereochemical requirements for enzymatic cleavage.
Jiang Y; Hu L
Bioorg Med Chem Lett; 2007 Jan; 17(2):517-21. PubMed ID: 17064897
[TBL] [Abstract][Full Text] [Related]
16. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
Low JE; Borch RF; Sladek NE
Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533
[TBL] [Abstract][Full Text] [Related]
17. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
18. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
[TBL] [Abstract][Full Text] [Related]
19. Alkylation of guanosine and deoxyguanosine by phosphoramide mustard.
Mehta JR; Przybylski M; Ludlum DB
Cancer Res; 1980 Nov; 40(11):4183-6. PubMed ID: 7471059
[TBL] [Abstract][Full Text] [Related]
20. Identification of phosphoramide mustard/DNA adducts using tandem mass spectrometry.
Cushnir JR; Naylor S; Lamb JH; Farmer PB; Brown NA; Mirkes PE
Rapid Commun Mass Spectrom; 1990 Oct; 4(10):410-4. PubMed ID: 2134189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
